186 related articles for article (PubMed ID: 35934678)
1. What has been learned by cytokine targeting of asthma?
Busse WW; Viswanathan R
J Allergy Clin Immunol; 2022 Aug; 150(2):235-249. PubMed ID: 35934678
[TBL] [Abstract][Full Text] [Related]
2. Targeting Downstream Type 2 Cytokines or Upstream Epithelial Alarmins for Severe Asthma.
Chan R; Stewart K; Misirovs R; Lipworth BJ
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1497-1505. PubMed ID: 35131510
[TBL] [Abstract][Full Text] [Related]
3. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics.
Porsbjerg CM; Sverrild A; Lloyd CM; Menzies-Gow AN; Bel EH
Eur Respir J; 2020 Nov; 56(5):. PubMed ID: 32586879
[TBL] [Abstract][Full Text] [Related]
4. Promises and challenges of biologics for severe asthma.
Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
[TBL] [Abstract][Full Text] [Related]
5. Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far?
Parulekar AD; Diamant Z; Hanania NA
Curr Opin Pulm Med; 2017 Jan; 23(1):3-11. PubMed ID: 27820746
[TBL] [Abstract][Full Text] [Related]
6. Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD.
Calderon AA; Dimond C; Choy DF; Pappu R; Grimbaldeston MA; Mohan D; Chung KF
Eur Respir Rev; 2023 Mar; 32(167):. PubMed ID: 36697211
[TBL] [Abstract][Full Text] [Related]
7. Sounding the alarmins-The role of alarmin cytokines in asthma.
Gauvreau GM; Bergeron C; Boulet LP; Cockcroft DW; Côté A; Davis BE; Leigh R; Myers I; O'Byrne PM; Sehmi R
Allergy; 2023 Feb; 78(2):402-417. PubMed ID: 36463491
[TBL] [Abstract][Full Text] [Related]
8. Biological treatments for severe asthma: A major advance in asthma care.
Busse WW
Allergol Int; 2019 Apr; 68(2):158-166. PubMed ID: 30792118
[TBL] [Abstract][Full Text] [Related]
9. Epithelial cell alarmin cytokines: Frontline mediators of the asthma inflammatory response.
Duchesne M; Okoye I; Lacy P
Front Immunol; 2022; 13():975914. PubMed ID: 36311787
[TBL] [Abstract][Full Text] [Related]
10. IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline.
Scott G; Asrat S; Allinne J; Keat Lim W; Nagashima K; Birchard D; Srivatsan S; Ajithdoss DK; Oyejide A; Ben LH; Walls J; Le Floc'h A; Yancopoulos GD; Murphy AJ; Sleeman MA; Orengo JM
Cytokine; 2023 Feb; 162():156091. PubMed ID: 36481478
[TBL] [Abstract][Full Text] [Related]
11. Biologics or immunotherapeutics for asthma?
Tay HL; Foster PS
Pharmacol Res; 2020 Aug; 158():104782. PubMed ID: 32275962
[TBL] [Abstract][Full Text] [Related]
12. [Alarmins and anti-alarmin biologics in asthma].
Görgülü B; Bavbek S
Tuberk Toraks; 2018 Jun; 66(2):166-175. PubMed ID: 30246661
[TBL] [Abstract][Full Text] [Related]
13. Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker-high and -low severe asthma.
Khalfaoui L; Symon FA; Couillard S; Hargadon B; Chaudhuri R; Bicknell S; Mansur AH; Shrimanker R; Hinks TSC; Pavord ID; Fowler SJ; Brown V; McGarvey LP; Heaney LG; Austin CD; Howarth PH; Arron JR; Choy DF; Bradding P
Allergy; 2022 Oct; 77(10):2974-2986. PubMed ID: 35579040
[TBL] [Abstract][Full Text] [Related]
14. Positioning of Tezepelumab in Severe Asthma.
Miralles-López JC; Antolín-Amérigo D; García-Moguel I; Domínguez-Ortega J; Delgado-Romero J; Quirce S
J Investig Allergol Clin Immunol; 2024 Feb; 34(1):1-11. PubMed ID: 37812191
[TBL] [Abstract][Full Text] [Related]
15. The interleukin-33 receptor ST2 is important for the development of peripheral airway hyperresponsiveness and inflammation in a house dust mite mouse model of asthma.
Zoltowska AM; Lei Y; Fuchs B; Rask C; Adner M; Nilsson GP
Clin Exp Allergy; 2016 Mar; 46(3):479-90. PubMed ID: 26609909
[TBL] [Abstract][Full Text] [Related]
16. The emergence of new biologics for severe asthma.
Eger KA; Bel EH
Curr Opin Pharmacol; 2019 Jun; 46():108-115. PubMed ID: 31229937
[TBL] [Abstract][Full Text] [Related]
17. Airway epithelial type-2 alarmin profiles: Blood eosinophil counts remain in memory.
Vernisse C; Tuaillon E; Suehs C; Gras D; Bedin AS; Charriot J; Knabe L; Vachier I; Chanez P; Petit A; Bourdin A
Eur J Immunol; 2023 Apr; 53(4):e2250101. PubMed ID: 36793156
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers in asthma, potential for therapeutic intervention.
Pasha MA; Hopp RJ; Habib N; Tang DD
J Asthma; 2024 Jun; ():1-16. PubMed ID: 38805392
[TBL] [Abstract][Full Text] [Related]
19. Molecular Targets for Biological Therapies of Severe Asthma.
Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
Front Immunol; 2020; 11():603312. PubMed ID: 33329598
[TBL] [Abstract][Full Text] [Related]
20. Epithelial alarmins: a new target to treat chronic respiratory diseases.
Nedeva D; Kowal K; Mihaicuta S; Guidos Fogelbach G; Steiropoulos P; Jose Chong-Neto H; Tiotiu A
Expert Rev Respir Med; 2023; 17(9):773-786. PubMed ID: 37746733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
